Amarin Corp Plc (AMRN)

[mrmainstreet]

Can someone explain to me what the end game is for generics here? It seems like the dog caught the car and now has to figure out WTH to do with it.

By winning this case they basically kill the market for Vascepa before it's built. How does that help them long term if AMRN will no longer be interested in promoting the drug if they lose 90% of the sales?

It seems like the court created a lose/lose/lose situation to me. AMRN loses everything they worked so hard for in the US market, the generics lose the ability to sell volume if no one is pushing the drug, and the consumers lose access to a game changing CV treatment.

So what is the best course of action for all? For AMRN it's appeal and win, losing 1-2 years of time that could be spent promoting Vascepa, but having unfettered access to the US market again. If the generics win the appeal they are almost worse off, because no one will sell the drug in the US, much less market it. So for them isn't settling better, so they get something?

Such a strange situation, but I am adding at these $5 levels when I can. The upside way more than the downside.